NASDAQ$IONS
Ionis Pharmaceuticals · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Ionis reported third quarter 2021 financial results, highlighting strategic advancements and pipeline development.
Ionis Pharmaceuticals reported $133 million in total revenues for Q3 2021. The company is well-capitalized with $2 billion in cash and investments. The company is advancing its Phase 3 pipeline and commercial readiness initiatives.
- Olezarsen Phase 3 CORE study in patients with sHTG was initiated.
- Donidalorsen Phase 2 data is set to be presented at the ACAAI Annual Meeting, with Phase 3 initiation on track for year-end.
- Tofersen Phase 3 VALOR study missed the primary endpoint, but signs of reduced disease progression were observed.
- Ionis remains on track to achieve its 2021 financial guidance, driven by increased R&D revenue in the fourth quarter.
Headline financials
Revenue & EPS history
Ionis · Revenue · Quarterly
$133M
Revenue by segment
Ionis · $151M total across 2 segments · Q2 2023
- Collaborative Agreement Rev$90M+130.8%59.6%
- SPINRAZA Royalties$61M+1.7%40.4%
Forward guidance
Ionis projects increased R&D revenue and expenses in the fourth quarter of 2021 and remains on track to achieve its 2021 financial guidance.
Tailwinds
- Increased R&D revenue is expected in Q4 2021.
- Advancement of partnered programs is expected.
- Company is well-capitalized with $2 billion in cash.
- Commercial readiness initiatives are advancing.
- Multiple product launches are anticipated, potentially starting in 2023.
Headwinds
- Increased expenses are projected in Q4 2021.
- Tofersen Phase 3 VALOR study missed primary endpoint.
- The Biogen Phase 3 VALOR study of tofersen in patients with SOD1-ALS did not meet the primary endpoint of change from baseline to week 28 in the ALS Functional Rating Scale-Revised (ALSFRS-R)
- Net loss attributable to Ionis’ common stockholders for the three and nine months ended September 30, 2021 increased compared with the same periods in the prior year
- SPINRAZA royalties decreased from $74 million to $67 million compared to Q3 2020
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+1.2%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+30.2%
Q3 2016
Best reaction
-13.5%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +5.1% | +6.6% | |
| Q4 2025 | -5.3% | -4.1% | -15.6% | |
| Q3 2025 | -2.3% | +0.1% | +12.5% | |
| Q1 2025 | +3.0% | +12.9% | +12.4% | |
| Q4 2024 | -0.4% | -0.2% | +3.0% | |
| Q3 2024 | -0.9% | +0.2% | -1.8% | |
| Q2 2024 | -0.7% | -4.9% | -3.6% | |
| Q1 2024 | -5.0% | -7.6% | -5.7% | |
| Q4 2023 | -0.8% | +3.9% | -3.7% | |
| Q3 2023 | +4.3% | +5.4% | +14.1% | |
| Q2 2023 | +0.7% | +0.8% | +4.2% | |
| Q1 2023 | +1.3% | -1.0% | +17.5% | |
| Q4 2022 | -4.0% | -5.3% | -11.2% | |
| Q3 2022 | +7.6% | +4.2% | -11.2% | |
| Q2 2022 | +0.9% | -3.5% | -3.2% | |
| Q1 2022 | -1.2% | -17.6% | -6.1% | |
| Q4 2021 | +3.4% | +10.9% | +19.3% | |
| Q3 2021 | +5.0% | +5.8% | -20.0% | |
| Q2 2021 | +4.2% | +2.0% | +4.5% | |
| Q1 2021 | -11.1% | -13.7% | -17.7% | |
| Q4 2020 | -4.7% | -3.6% | -23.4% | |
| Q3 2020 | +3.7% | +6.6% | +9.0% | |
| Q2 2020 | -4.6% | -8.7% | -6.1% | |
| Q1 2020 | -7.7% | -2.7% | -0.3% | |
| Q4 2019 | -3.6% | -5.4% | -10.7% | |
| Q3 2019 | +1.8% | +4.2% | +18.8% | |
| Q2 2019 | +6.6% | +6.2% | -3.6% | |
| Q1 2019 | +0.9% | -2.8% | -7.2% | |
| Q4 2018 | +15.2% | +14.4% | +31.7% | |
| Q3 2018 | +5.4% | -0.0% | +8.8% | |
| Q2 2018 | +4.4% | +11.6% | +1.9% | |
| Q1 2018 | +7.4% | +3.7% | +12.9% | |
| Q4 2017 | +2.8% | -4.7% | -14.2% | |
| Q3 2017 | +0.9% | +3.0% | -0.6% | |
| Q2 2017 | -8.6% | -11.0% | +7.4% | |
| Q1 2017 | -2.6% | +3.9% | +10.3% | |
| Q4 2016 | +5.4% | +16.6% | -13.8% | |
| Q3 2016 | +30.2% | +51.0% | +44.9% | |
| Q2 2016 | +0.1% | -2.5% | -14.1% | |
| Q1 2016 | -8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | +14.8% | — | — | |
| Q2 2015 | +1.0% | — | — | |
| Q1 2015 | +1.2% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | +6.3% | — | — | |
| Q1 2014 | -6.5% | — | — | |
| Q4 2013 | -9.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | -12.4% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -7.0% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | +7.6% | — | — | |
| Q4 2011 | +2.8% | — | — | |
| Q3 2011 | -13.5% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -2.7% | — | — | |
| Q1 2011 | +2.8% | — | — | |
| Q4 2008 | -1.6% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q4 2009 | -3.8% | — | — | |
| Q2 2010 | -3.8% | — | — | |
| Q2 2009 | -3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro